Alphyn's AB-101 platform has multiple bioactive compounds and therefore multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics that have potential safety, efficacy and regulatory marketing authorization advantages.

Source: https://www.prnewswire.com/news-releases/alphyn-biologics-reports-positive-results-from-first-cohort-of-phase-2a-trial-of-mild-to-moderate-atopic-dermatitis-treatment-301713110.html